Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry

被引：10

作者：

Vallard, Alexis ^{[1
]}

Guy, Jean-Baptiste ^{[1
]}

Ndong, Sylvie Mengue ^{[1
]}

Vial, Nicolas ^{[1
]}

Rivoirard, Romain ^{[2
]}

Auberdiac, Pierre ^{[3
]}

Mery, Benoite ^{[2
]}

Langrand-Escure, Julien ^{[1
]}

Espenel, Sophie ^{[1
]}

Moncharmont, Coralie ^{[1
]}

Ben Mrad, Majed ^{[1
]}

Diao, Peng ^{[1
]}

Goyet, Dominique ^{[4
]}

Magne, Nicolas ^{[1
]}

机构：

[1] Lucien Neuwirth Canc Inst, Dept Radiotherapy, 108 Bis,Ave Albert Raimond,BP 60008, F-42271 St Priest En Jarez, France

[2] Lucien Neuwirth Canc Inst, Dept Med Oncol, St Priest En Jarez, France

[3] Claude Bernard Clin, Dept Radiotherapy, Albi, France

[4] Lucien Neuwirth Canc Inst, Dept Med Phys, St Priest En Jarez, France

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2016年 / 38卷 / 07期

关键词：

volumetric-modulated arc therapies; intensity-modulated radiotherapy; parotid gland; submandibular gland; dosimetry; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; PAROTID-GLAND; IMRT; XEROSTOMIA; AMIFOSTINE;

D O I：

10.1002/hed.24398

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Background. Despite radiotherapy (RT) technical improvements, high salivary dysfunction rates are still reported in patients with head and neck squamous cell carcinoma (HNSCC). The purpose of the present study was to report salivary glands dosimetry with volumetric-modulated arc therapy (VMAT) and intensity-modulated RT (IMRT). Methods. Dosimetry of consecutive patients receiving IMRT or VMAT for proven HNSCC between 2007 and 2013 were retrospectively reviewed. Results. Data of 609 patients were studied. Mean dose, mean maximum dose, and mean percentage of salivary gland volume receiving at least 26 Gy (V26) of the contralateral parotid were 24.50 Gy (range, 0-70.4 Gy), 39.08 Gy (range, 0.38-76.45 Gy), and 40.92% (range, 0% to 100%), respectively. Mean and maximum dose on contralateral submandibular gland were 48.18 Gy (range, 0.19-70.73 Gy), and 61.25 Gy (range, 0-75.8 Gy), respectively. Conclusion. Target volume coverage still has to be prioritized over organs at risk (OAR) sparing with new RT techniques. Submandibular glands are not sufficiently taken into account in guidelines. (C) 2016 Wiley Periodicals, Inc.

引用

页码：1028 / 1034

页数：7

共 37 条

[21]

Lapeyre M, 2010, Cancer Radiother, V14 Suppl 1, pS43, DOI 10.1016/S1278-3218(10)70007-X

[22] Larynx preservation in pyriform sinus cancer: Preliminary results of a European organization for research and treatment of cancer phase III trial [J].

Lefebvre, JL ;

Chevalier, D ;

Luboinski, B ;

Kirkpatrick, A ;

Collette, L ;

Sahmoud, T .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (13) :890-899

[23] The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy [J].

Marcu, L. G. .

EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (02) :116-123

[24] RELATIVE CONTRIBUTIONS OF DIFFERENT SALIVARY-GLANDS TO BLOOD-GROUP ACTIVITY OF WHOLE SALIVA IN HUMANS [J].

MILNE, RW ;

DAWES, C .

VOX SANGUINIS, 1973, 25 (04) :298-307

[25] SOME FACTORS INFLUENCING SALIVARY FUNCTION WHEN TREATING WITH RADIOTHERAPY [J].

MIRA, JG ;

WESCOTT, WB ;

STARCKE, EN ;

SHANNON, IL .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (04) :535-541

[26] Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy:: Comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine [J].

Muenter, Marc W. ;

Hoffner, Simone ;

Hof, Holger ;

Herfarth, Klaus K. ;

Haberkorn, Uwe ;

Rudat, Volker ;

Huber, Peter ;

Debus, Juergen ;

Karger, Christian P. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (03) :651-659

[27] Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy [J].

Murdoch-Kinch, Carol-Anne ;

Kim, Hyugnjin M. ;

Vineberg, Karen A. ;

Ship, Jonathan A. ;

Eisbruch, Avraham .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (02) :373-382

[28] Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial [J].

Nutting, Christopher M. ;

Morden, James P. ;

Harrington, Kevin J. ;

Urbano, Teresa Guerrero ;

Bhide, Shreerang A. ;

Clark, Catharine ;

Miles, Elizabeth A. ;

Miah, Aisha B. ;

Newbold, Kate ;

Tanay, MaryAnne ;

Adab, Fawzi ;

Jefferies, Sarah J. ;

Scrase, Christopher ;

Yap, Beng K. ;

A'Hern, Roger P. ;

Sydenham, Mark A. ;

Emson, Marie ;

Hall, Emma .

LANCET ONCOLOGY, 2011, 12 (02) :127-136

[29] Evaluation of the trade-offs encountered in planning and treating locally advanced head and neck cancer: intensity-modulated radiation therapy vs dual-arc volumetric-modulated arc therapy [J].

Oliver, M. ;

McConnell, D. ;

Romani, M. ;

McAllister, A. ;

Pearce, A. ;

Andronowski, A. ;

Wang, X. ;

Leszczynski, K. .

BRITISH JOURNAL OF RADIOLOGY, 2012, 85 (1020) :1539-1545

[30] The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy [J].

Rudat, Volker ;

Muenter, Mark ;

Rades, Dirk ;

Groez, Knut A. ;

Bajrovic, Amira ;

Haberkorn, Uwe ;

Brenner, Winfried ;

Debus, Juergen .

RADIOTHERAPY AND ONCOLOGY, 2008, 89 (01) :71-80

← 1 2 3 4 →